This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Varian's ProBeam Compact System Picked by University of Miami
by Zacks Equity Research
Varian (VAR) sees notable developments in its Proton Solutions business of late.
DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
DexCom (DXCM) has various favorable factors to maintain the current high.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.
Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.
What's in Store for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.
Veeva (VEEV) Introduces MuleSoft Connector for Vault Platform
by Zacks Equity Research
Veeva's (VEEV) Vault platform sees a slew of developments in recent times.
Allscripts' (MDRX) Veradigm Collaborates With Komodo Health
by Zacks Equity Research
Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.
Here's Why You Should Add Stryker (SYK) to Your Portfolio
by Zacks Equity Research
Stryker (SYK) gains from core segments in the second quarter of 2019.
Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance
by Zacks Equity Research
Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.
Here's Why You Should Snap Up Baxter International (BAX) Now
by Zacks Equity Research
For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.
Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.
Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised
by Zacks Equity Research
Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.
Nevro (NVRO) Q2 Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
Nevro (NVRO) sees dismal segmental performance in Q2.
Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered
by Zacks Equity Research
Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.
Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.
Allscripts (MDRX) Q2 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.
Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.
Adidas Slips, Lyft Climbs, Uber Earnings & Why Intuitive Surgical Stock is a Strong Buy | Free Lunch
by Benjamin Rains
On today's episode of Free Lunch here at Zacks, Associate Stock Strategist Ben Rains offers a quick global economic update. The episode also dives into Adidas (ADDYY), Lyft (LYFT), and Uber (UBER) earnings, and more...
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
LHC Group (LHCG) second-quarter results benefit from home health and hospice admissions and higher revenues.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.
Wright Medical (WMGI) Earnings Beat in Q2, Guidance Slashed
by Zacks Equity Research
Wright Medical (WMGI) gains from Upper and Lower Extremities units in Q2; slashes 2019 view.
Cardiovascular Systems (CSII) Earnings Match Estimates in Q4
by Zacks Equity Research
We are upbeat about the year-over-year uptick in Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.
CVS Health (CVS) Beats on Q2 Earnings, Raises '19 Guidance
by Zacks Equity Research
CVS Health's (CVS) second-quarter top-line growth in Pharmacy Services segment is backed by an uptick in specialty services.
Avanos (AVNS) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Avanos (AVNS) second-quarter results benefit from higher revenues, strong segmental performance and expansion in margins.